-+ 0.00%
-+ 0.00%
-+ 0.00%

Rosemont Pharmaceuticals agrees to acquire Aytu BioPharma for $2.70 per share

PUBT·11/16/2026 21:11:30
Listen to the news
Rosemont Pharmaceuticals agrees to acquire Aytu BioPharma for $2.70 per share
  • Rosemont Pharmaceuticals agreed to acquire Aytu BioPharma for $2.70 per share in cash through a tender offer followed by a merger.
  • The price represents premiums of 41.1% to the 30-day volume-weighted average price and 51.7% to the November 13, 2026, closing price.
  • Closing is expected in late December 2026, subject to a majority of outstanding common shares being tendered and certain warrants exercised or terminated.
  • Nantahala Capital Management affiliates, Stonepine Capital Management affiliates and Aytu’s directors and officers signed tender and support agreements.
  • The acquisition would expand Rosemont’s US business with an established portfolio focused on adult and pediatric central nervous system treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-037155), on November 16, 2026, and is solely responsible for the information contained therein.